GB201009173D0 - Treatment of pain - Google Patents

Treatment of pain

Info

Publication number
GB201009173D0
GB201009173D0 GBGB1009173.4A GB201009173A GB201009173D0 GB 201009173 D0 GB201009173 D0 GB 201009173D0 GB 201009173 A GB201009173 A GB 201009173A GB 201009173 D0 GB201009173 D0 GB 201009173D0
Authority
GB
United Kingdom
Prior art keywords
vegfr2
vegfxxx
isoforms
agonist
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1009173.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Priority to GBGB1009173.4A priority Critical patent/GB201009173D0/en
Publication of GB201009173D0 publication Critical patent/GB201009173D0/en
Priority to PCT/GB2011/051018 priority patent/WO2011148200A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The invention provides an active agent comprising one or more VEGFR2 agonist for use in treating or preventing VEGFR2-mediated non-inflammatory pain. The VEGFR2 agonist may be selected from the VEGFxxxb family of proteins, particularly VEGF165b, soluble VEGF receptors having activity as inhibitors of VEGFR2 antagonists and VEGFxxx isoforms that have the C-terminal hexapeptide corresponding to expression immediately after exon 7, or VEGFxxx isoforms that lack neuropilin binding mediating portions of the amino acid sequence.
GBGB1009173.4A 2010-05-28 2010-05-28 Treatment of pain Ceased GB201009173D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1009173.4A GB201009173D0 (en) 2010-05-28 2010-05-28 Treatment of pain
PCT/GB2011/051018 WO2011148200A1 (en) 2010-05-28 2011-05-27 Treatment of pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1009173.4A GB201009173D0 (en) 2010-05-28 2010-05-28 Treatment of pain

Publications (1)

Publication Number Publication Date
GB201009173D0 true GB201009173D0 (en) 2010-07-14

Family

ID=42371319

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1009173.4A Ceased GB201009173D0 (en) 2010-05-28 2010-05-28 Treatment of pain

Country Status (2)

Country Link
GB (1) GB201009173D0 (en)
WO (1) WO2011148200A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN03969A (en) 2012-10-17 2015-10-02 Univ Bristol
GB201406956D0 (en) 2014-04-17 2014-06-04 Univ Nottingham Compounds
GB201518365D0 (en) 2015-10-16 2015-12-02 Exonate Ltd Compounds
JP7261793B2 (en) 2017-09-27 2023-04-20 エクソネイト リミテッド SRPK1 inhibitor
GB202010829D0 (en) 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
WO2003012105A2 (en) 2001-08-01 2003-02-13 University Of Bristol Vegf isoform
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
GB0803912D0 (en) 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb

Also Published As

Publication number Publication date
WO2011148200A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
GB2520897A (en) Compositions and methods for treating cutaneous scarring
MX2011006685A (en) Membrane type-1 matrix metalloprotein inhibitors and uses thereof.
UA109878C2 (en) Isoquinolinone derivatives, pharmaceutical composition based on them (variants), and method of treating diseases (variants)
UA101362C2 (en) Protein tyrosine kinase activity inhibitors
CO6761350A2 (en) Derivatives of 2,3-dihydroimidazo [1,2-c] quinazoline substituted with amino alcohols that are useful for treating hyperproliferative disorders and diseases associated with angiogenesis
EA201001204A1 (en) METHODS AND COMPOSITIONS IN WHICH APPLY KLOTHO-FGF POLYPEPTIDES FUSED
EA201100427A1 (en) HETEROCYCLIC KINASE INHIBITORS
EA201491008A1 (en) COMBINATION OF ANTHAGONIST CRTH2 AND PROTONE PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHIL ESOPHAGITIS
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
EA200802135A1 (en) PHARMACEUTICAL COMPOSITIONS OF ANTAGONISTIC ANTIBODY TO CD40
EA201690033A3 (en) MORPHINAN COMPOUNDS
IL192557A (en) Substituted imidazole derivatives and their use as ptpase inhibitors
IN2012DN02177A (en)
GB201009173D0 (en) Treatment of pain
MY167232A (en) Polypeptides binding to human complement c5
MX351262B (en) Composition for transdermal delivery of cationic active agents.
WO2009052489A3 (en) Novel inhibitors of mammalian tight junction opening
GB2481712B (en) Composition comprising vascular endothelial growth factor (VEGF) for the treatment of hair loss
MY150600A (en) Use of opioid antagonists for treating urinary retention
MY157319A (en) Inhibitors of protein tyrosine kinase activity
IN2013MN00758A (en)
AU2019284019A1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
MD20160007A2 (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof
MX2009000359A (en) Methods for treating and limiting fibrotic disorders and keloids.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)